Topical silver sulphadiazine--a new drug for ocular keratomycosis

Mohan, M; Gupta, S K; Kalra, V K; Vajpayee, R B; Sachdev, M S
March 1988
British Journal of Ophthalmology;Mar1988, Vol. 72 Issue 3, p192
Academic Journal
No abstract available.


Related Articles

  • Keratitis by Paecilomyces lilacinus: A case report from Sub-Himalayan region. Sharma, V.; Angrup, A.; Panwar, P.; Verma, S.; Singh, D.; Kanga, A. // Indian Journal of Medical Microbiology;Oct-Dec2015, Vol. 33 Issue 4, p585 

    Paecilomyces lilacinus is a filamentous fungus found in soil and air, which is a rare cause of ocular infection. The majority of case reports involving P. lilacinus among healthy hosts are of endophthalmitis and keratitis. We report a rare case of keratomycosis by P. lilacinus, in an...

  • Rare case of fungal keratitis caused by Corynespora cassiicola. Yamada, Hiroki; Takahashi, Nobumichi; Hori, Nobuhide; Asano, Yuko; Mochizuki, Kiyofumi; Ohkusu, Kiyofumi; Nishimura, Kazuko // Journal of Infection & Chemotherapy (Springer Science & Business;Dec2013, Vol. 19 Issue 6, p1167 

    We describe a 76-year-old male farmer with no diabetes mellitus and no history of ocular trauma from soil or plants who developed a corneal infection from a plant pathogen. The organism was identified as Corynespora cassiicola based on both the morphological characteristics and the sequence of...

  • B&L's Combination Drug Approved.  // Review of Optometry;4/15/2005 Supplement, Vol. 142, p1 

    Reports on the approval given to the New Drug Application for topical antibiotic-steroid combination product used in inflammatory ocular conditions from Bausch & Lomb Inc. by the U.S. Food and Drug Administration.

  • Identification and sensitivity of two rare fungal species isolated from two patients with Fusarium keratomycosis. Mochizuki, Kiyofumi; Shiraki, Ikumi; Murase, Hiroki; Ohkusu, Kiyofumi; Nishimura, Kazuko // Journal of Infection & Chemotherapy;Dec2012, Vol. 18 Issue 6, p939 

    We report two cases of Fusarium keratomycosis in which molecular analysis was used to identify two rare causative Fusarium species. A 65-year-old woman was diagnosed with Fusarium keratomycosis caused by F. equiseti, confirmed by sequencing the internal transcribed spacer (ITS) region and...

  • Novel Strategies for Anterior Segment Ocular Drug Delivery. Cholkar, Kishore; Patel, Sulabh P.; Vadlapudi, Aswani Dutt; Mitra, Ashim K. // Journal of Ocular Pharmacology & Therapeutics;Mar2013, Vol. 29 Issue 2, p106 

    Research advancements in pharmaceutical sciences have led to the development of new strategies in drug delivery to anterior segment. Designing a new delivery system that can efficiently target the diseased anterior ocular tissue, generate high drug levels, and maintain prolonged and effective...

  • Ocular surface therapy, amniotic membranes grow in popularity. Charters, Lynda; Hersh, Peter S.; Donnenfeld, Eric D. // Ophthalmology Times;Dec2014, Vol. 39 Issue 22, p40 

    The article focuses on the growing popularity of ocular surface therapy and amniotic membrane onlays among refractive and cataract surgeons in the U.S. as of December 2014. Topics discussed include the popularity of ocular surface therapy in conjunction with serum tears to manage the ocular...

  • Early allergy season springs into action. Mussoline, Joseph F. // Ophthalmology Times;5/1/2003, Vol. 28 Issue 9, p18 

    Discusses trends in the treatment and diagnosis of seasonal ocular allergy. Role of mast cells in the context of ocular allergy; Symptom mediators; Novel uses for existing drugs; Importance of treating topical disease with topical medications.

  • A critical look at ocular allergy drugs. Titi, Mark Joseph // American Family Physician;6/1/1996, Vol. 53 Issue 8, p2637 

    Presents a critical look at topical ocular allergy drugs used for the treatment of allergic conjunctivitis. Approach in using chemotherapeutic protocols; Efficacy studies; Antihistamine-vasoconstrictors preparations; Lodoxamide; Ketorolac tromethamine; Levocabastine; Topical ocular corticosteroids.

  • Bausch + Lomb submits new drug application for Prolensa.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, p24 

    The article reports that Bausch + Lomb has submitted a new drug application to the U.S. FDA for approval of Prolensa (bromfenac ophthalmic solution), a once daily topical non-steroidal anti-inflammatory drug (NSAID) for the treatment of ocular inflammation and pain after cataract surgery.

  • Industry Pipeline.  // Ocular Surgery News;1/25/2016, Vol. 34 Issue 2, p35 

    The article presents eye care industry updates on topics including the U.S. Food and Drug Administration (FDA) clearance of an imaging system PanoCam LT, Ocular Therapeutix's new drug Dextenza, and premarket approval submitted by eye care company Revision Optics.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics